Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial.

Area of Science:

• Reproductive Health
• Pharmacology
• Clinical Trials

Background:

• Emergency contraception is crucial for preventing unintended pregnancies.
• Mifepristone is a widely used emergency contraceptive.
• Gestrinone, another progestin, has been proposed as an alternative.

Purpose of the Study:

• To compare the efficacy and safety of gestrinone versus mifepristone for emergency contraception.
• To determine if gestrinone is a non-inferior alternative to mifepristone.

Main Methods:

• A randomized, double-blind trial involving 998 healthy women in China.
• Participants received either a single 10 mg dose of gestrinone or 10 mg of mifepristone within 72 hours of unprotected intercourse.
• Women were monitored for pregnancy and side effects until their next expected menstrual period.

Main Results:

• No significant difference in post-treatment pregnancy rates between the two groups (2.4% for gestrinone vs. 1.8% for mifepristone; P=.51).
• The majority of women experienced timely menstruation.
• No significant differences in reported side effects were observed between the gestrinone and mifepristone groups.

Conclusions:

• Single-dose 10 mg gestrinone is as effective as 10 mg mifepristone for emergency contraception.
• Gestrinone represents a viable alternative emergency contraceptive option with comparable efficacy and safety profiles.